Fresh analysis reveals that individuals who come off popular weight-loss injections like Wegovy and Mounjaro may regain lost weight far faster than those who stop conventional lifestyle regimens.
Research printed in a major medical journal points out that while obese individuals often shed about a fifth of their body weight while using the jabs, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.
"People purchasing these medications must be cognizant of the potential of quick rebound weight gain when the medication concludes," stated expert Dr. Susan Jebb.
That rate of regain suggests a reversion to starting mass in about a year and a half.
Comparing Therapies
The research, which reviewed dozens of studies involving thousands of patients, contrasted the outcomes of the injectable medications with other pills.
Researchers point out that individuals who shed pounds through dieting usually have a slower creep back—approximately 100 grams monthly—once they finish.
Explaining the Rapid Regain
Experts propose the way of the drugs accounts for the accelerated rebound.
The injections copy a body's own chemical called GLP-1, which helps regulate appetite.
"Artificially providing GLP-1 levels several times higher than normal might result in the system to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication leads to appetite is uncontrolled, making excessive eating far more likely."
An Ongoing Issue?
Health authorities advise the jabs for people with obesity-related health risks, accompanied by recommended lifestyle changes.
A number of clinicians say that, given the likelihood of weight regain, the therapy is often long-term.
This view is reinforced by drug manufacturers, who state that the findings "highlight the persistent character of excess weight," akin to managing diseases like high blood pressure.
Patient Experiences
Individuals who have discontinued the medication explain a sudden return of hunger.
"It felt as if a trigger flipping and you become starving," recalled one woman.
This challenge is compounded if users have not adopted lasting dietary or behavioural changes during treatment.
Significant Adoption
Figures suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is higher among females than men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
In conclusion, researchers caution that while these medications are potent agents for weight loss, they are not a magic solution and long-term success relies on combined lifestyle support.
